Urology Devices Market Size, Share, Growth, and Industry Analysis, By Type (Endoscopes,Lasers and Lithotripsy Devices,Dialysis Devices,Other), By Application (Hospitals and Clinics,Dialysis Centers,Others), Regional Insights and Forecast to 2035

Urology Devices Market Overview

The global Urology Devices Market is forecast to expand from USD 47218.81 million in 2026 to USD 50656.34 million in 2027, and is expected to reach USD 88855.95 million by 2035, growing at a CAGR of 7.28% over the forecast period.

The global Urology Devices Market holds a significant position in the medical technology industry, with instruments accounting for 67.58% of total device usage worldwide. Hospitals and clinics remain the largest end-users, representing 68.55% of total demand. The kidney-stone management segment alone accounts for 36.41% of all urology-related procedures, while minimally invasive technologies contribute 46.13% of the technology segment. North America leads with 37.45% of the global share, followed by Europe at 27% and Asia-Pacific at 19%. Growth in single-use endoscopes and robotic-assisted surgeries is transforming procedural approaches in both developed and emerging markets.

The United States accounts for 27% of the global Urology Devices Market, holding the largest single-country share. Hospitals and clinics dominate with more than 70% of the national market usage. Surgical instruments, including endoscopes and lithotripsy devices, represent 41.8% of all urology devices in the country. Minimally invasive technologies make up 46.13% of usage, driven by the rising demand for robotic procedures. The U.S. also leads in adoption of single-use cystoscopes, contributing to improved infection control and reducing reprocessing times by over 35% in high-volume hospitals.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 37.45% share held by North America due to advanced healthcare facilities and high patient volumes.
• Major Market Restraint: 67.58% concentration in instruments limits consumables expansion.
• Emerging Trends: 68.55% demand driven by hospitals and clinics, sustaining institutional dominance.
• Regional Leadership: United States holds 27% of global market volume.
• Competitive Landscape: Top two companies control over 25% of global share.
• Market Segmentation: Minimally invasive devices make up 46.13% of technology adoption.
• Recent Development: Ambulatory surgical centers in Asia-Pacific grew their share by 8.78%.

Urology Devices Market Latest Trends

The Urology Devices Market is witnessing a sharp increase in demand for single-use devices, particularly in endoscopy. Endoscopes, which account for a large portion of the 67.58% instrument segment, are now increasingly being replaced with disposable versions to reduce cross-contamination. Hospitals and clinics, with 68.55% end-user dominance, are leading adopters of advanced lithotripsy devices for stone fragmentation. Minimally invasive surgery equipment represents 46.13% of the technology segment, reflecting a global shift toward less invasive procedures that shorten hospital stays. Kidney-stone management remains a high-priority treatment area, making up 36.41% of disease-specific device demand. Robotic-assisted urology surgeries have grown significantly, particularly in prostate and bladder procedures, with units deployed in over 30% of high-capacity hospitals in developed regions. Ambulatory surgical centers have increased their usage share by 8.78%, becoming critical channels for single-use technologies and portable systems.

Urology Devices Market Dynamics

DRIVER

"Rising prevalence of kidney-stone disorders fueling demand for advanced treatment devices."

Kidney-stone management constitutes 36.41% of the global disease-based market, generating substantial procedural volumes. The availability of precision lithotripsy devices and flexible ureteroscopes has increased treatment success rates in hospitals and clinics, which account for 68.55% of total usage. Minimally invasive devices, representing 46.13% of technology share, have also improved recovery outcomes, further driving adoption.

RESTRAINT

"High reliance on reusable instruments restricting consumables market growth."

The instruments category dominates with 67.58% share, much of which consists of high-cost reusable systems. This concentration limits rapid penetration of consumables in emerging markets and slows adoption in lower-infrastructure healthcare environments.

OPPORTUNITY

"Expansion of single-use endoscopes and outpatient surgical networks."

Ambulatory surgical centers have grown their share by 8.78%, offering a cost-effective setting for procedures that require compact and low-maintenance devices. Single-use endoscopes are increasingly deployed in these facilities, reducing sterilization needs and supporting same-day treatments.

CHALLENGE

"Uneven distribution of advanced technologies across regions."

North America and Europe together account for over 64% of total market volume, leaving Asia-Pacific, South America, and Middle East & Africa with limited access to advanced robotics, lasers, and minimally invasive equipment, constraining global scalability.

Urology Devices Market Segmentation

The Urology Devices Market is segmented by type and application. Instruments hold 67.58% share, consumables are smaller but growing, and kidney-stone management leads with 36.41% of disease-related demand. Hospitals and clinics account for 68.55% of usage, while ambulatory centers are the fastest-growing application.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Endoscopes: Used in over 60% of all diagnostic and therapeutic urology procedures. Flexible and rigid models are key tools in kidney-stone and bladder disease treatments. Single-use endoscopes are reducing reprocessing times by up to 35% in high-volume centers.

Endoscopes are estimated at USD 12,588.16 million in 2025, capturing 28.6% of the Urology Devices Market, with a 7.6% CAGR through 2034, supported by high cystoscopy and ureteroscopy volumes, single-use penetration above 30%, and accelerated replacement cycles.

Top 5 Major Dominant Countries in the Endoscopes Segment

• United States: USD 3,650.57 million, 29.0% endoscopes share, 6.9% CAGR, driven by procedure density above 1,000 per million population and flexible scope adoption exceeding 60% across tertiary systems.
• China: USD 2,139.99 million, 17.0% share, 8.5% CAGR, with expanding urology suites across top 100 cities and single-use adoption rising by 18% year-over-year in Grade-A hospitals.
• Germany: USD 1,258.82 million, 10.0% share, 5.4% CAGR, supported by endoscopy suites in over 85% of university hospitals and strong reprocessing infrastructure across federal states.
• Japan: USD 1,132.93 million, 9.0% share, 4.8% CAGR, anchored by high endoscopy utilization in metropolitan centers and aging demographics requiring increased diagnostic throughput.
• India: USD 1,007.05 million, 8.0% share, 9.2% CAGR, propelled by capacity additions in 200+ private chains and expanding day-care endourology footprints in Tier-2 and Tier-3 cities.

Lasers and Lithotripsy Devices: Essential for kidney-stone management, which accounts for 36.41% of disease-specific share. Laser systems offer high-precision stone fragmentation, increasing treatment success rates in hospitals and specialized clinics.

Lasers and lithotripsy devices are projected at USD 9,859.26 million in 2025, equating to 22.4% share, delivering a 7.9% CAGR, supported by kidney-stone prevalence above 10% in several markets and rising holmium/Thulium fiber laser installations.

Top 5 Major Dominant Countries in the Lasers and Lithotripsy Devices Segment

• United States: USD 2,662.00 million, 27.0% lithotripsy share, 8.1% CAGR, underpinned by broad laser access in over 70% of tertiary hospitals and strong ambulatory stone programs.
• China: USD 1,971.85 million, 20.0% share, 9.4% CAGR, with rapid fiber-laser deployment in provincial centers and increased ESWL utilization across public networks.
• Germany: USD 887.33 million, 9.0% share, 6.1% CAGR, supported by procurement consolidation and guideline-driven stone management in urology clinics nationwide.
• Japan: USD 788.74 million, 8.0% share, 5.0% CAGR, reflecting stable ESWL volumes and gradual fiber-laser upgrades in high-volume facilities.
• India: USD 690.15 million, 7.0% share, 10.2% CAGR, propelled by cost-efficient laser platforms and strong private hospital expansion across eight large states.

Dialysis Devices: Vital for chronic kidney disease care, deployed in both hospitals and dialysis centers. Units are integrated with advanced monitoring systems to improve patient outcomes, representing a steady portion of the instrument segment.

Dialysis devices account for USD 16,197.35 million in 2025, representing the category’s largest 36.8% share, growing at 6.3% CAGR, anchored by chronic kidney disease prevalence above 9% and steady in-center and home modality placements.

Top 5 Major Dominant Countries in the Dialysis Devices Segment

• United States: USD 3,887.37 million, 24.0% dialysis share, 5.8% CAGR, with mature provider networks, high device renewal rates, and home dialysis penetration exceeding 12% of active patients.
• China: USD 2,429.60 million, 15.0% share, 7.6% CAGR, supported by capacity expansion in prefecture-level cities and increased reimbursement alignment for ESRD therapy.
• Japan: USD 1,781.71 million, 11.0% share, 4.2% CAGR, reflecting stable high utilization and device standardization in dedicated dialysis hospitals.
• Germany: USD 1,295.79 million, 8.0% share, 5.0% CAGR, driven by consistent patient throughput and integrated monitoring systems across centers.
• India: USD 1,133.81 million, 7.0% share, 8.7% CAGR, with device rollouts in 500+ programmatic centers and rapid private network growth.

Other Devices: Includes robotic surgical systems, urodynamic analyzers, and imaging platforms. Robotic systems are used in more than 30% of complex urology surgeries in high-capacity hospitals, driving the 46.13% share of minimally invasive technologies.

Other devices (robotic systems, urodynamics, imaging, accessories) total USD 5,369.78 million in 2025, forming 12.2% share, with 7.0% CAGR, lifted by robotic urology penetration above 30% in tertiary hubs and expanding urodynamics adoption.

Top 5 Major Dominant Countries in the Other Segment

• United States: USD 1,342.44 million, 25.0% share, 6.8% CAGR, reflecting broad robotic platforms and advanced urodynamic labs in major academic centers.
• China: USD 966.56 million, 18.0% share, 8.6% CAGR, driven by surgical robotics diffusion and per-procedure accessory uptake in large hospitals.
• Germany: USD 536.98 million, 10.0% share, 5.1% CAGR, with strong device standardization and imaging upgrades in reference centers.
• Japan: USD 429.58 million, 8.0% share, 4.7% CAGR, supported by robotic programs in metropolitan university hospitals and specialized clinics.
• India: USD 375.88 million, 7.0% share, 9.0% CAGR, fueled by private consortium purchases and rising urodynamic testing volumes.

BY APPLICATION

Hospitals and Clinics: Account for 68.55% of the total market, utilizing the widest range of instruments and technologies for complex and routine procedures.

Hospitals and clinics are estimated at USD 30,149.97 million in 2025, holding 68.5% share with a 7.1% CAGR, supported by high OR utilization, complex case mix above 60%, and large installed bases across top health systems.

Top 5 Major Dominant Countries in the Hospitals and Clinics Application

• United States: USD 8,441.99 million, 28.0% application share, 6.6% CAGR, reflecting broad robotic and laser access in more than 70% of tertiary facilities.
• China: USD 4,823.99 million, 16.0% share, 8.6% CAGR, driven by operating-room expansion and rapid endoscopy fleet growth.
• Germany: USD 2,713.50 million, 9.0% share, 5.3% CAGR, anchored by university hospitals and guideline-based treatment pathways.
• Japan: USD 2,412.00 million, 8.0% share, 4.9% CAGR, with high instrument utilization and balanced inpatient/outpatient mix.
• India: USD 2,110.50 million, 7.0% share, 9.1% CAGR, propelled by multispecialty chains and rising minimally invasive volumes.

Dialysis Centers: Specialized facilities that cater to chronic kidney disease patients, with steady equipment demand.

Dialysis centers represent USD 9,022.98 million in 2025, accounting for 20.5% share with 6.8% CAGR, supported by ESRD prevalence above 1,200 per million in several markets and systematic device renewal cycles.

Top 5 Major Dominant Countries in the Dialysis Centers Application

• United States: USD 1,985.06 million, 22.0% application share, 6.1% CAGR, reflecting dense center networks and home modality incentives.
• China: USD 1,624.14 million, 18.0% share, 7.4% CAGR, aligning with expanding provincial capacity and device standardization.
• Japan: USD 1,082.76 million, 12.0% share, 4.4% CAGR, with consistent long-term utilization and high machine uptime.
• Germany: USD 812.07 million, 9.0% share, 5.0% CAGR, driven by integrated monitoring and service contracts.
• India: USD 721.84 million, 8.0% share, 8.2% CAGR, benefiting from public-private programs and new unit additions.

Others: Includes ambulatory surgical centers, which have grown by 8.78% in share, largely driven by adoption of portable and single-use devices.

Others contribute USD 4,841.60 million in 2025, equal to 11.0% share with 8.2% CAGR, boosted by ambulatory stone management growth above 12% and single-use endoscopes reducing reprocessing time by over 30%.

Top 5 Major Dominant Countries in the Others Application

• United States: USD 1,258.82 million, 26.0% application share, 8.0% CAGR, led by ASC networks with expanding urology suites.
• China: USD 919.90 million, 19.0% share, 9.2% CAGR, with outpatient expansions in top metropolitan clusters.
• Germany: USD 435.74 million, 9.0% share, 6.0% CAGR, supported by specialized day-care centers.
• Japan: USD 387.33 million, 8.0% share, 5.4% CAGR, reflecting steady ambulatory adoption.
• India: USD 338.91 million, 7.0% share, 9.8% CAGR, driven by cost-effective day-care pathways.

Urology Devices Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America leads with 37.45% global share, Europe holds 27%, Asia-Pacific has 19%, and the rest is split between South America and Middle East & Africa. Hospitals and clinics dominate in all regions, but ambulatory center growth is most notable in Asia-Pacific.

North America

North America remains the largest and most advanced market, commanding 37.45% of the global Urology Devices Market share. The United States alone contributes 27% of global demand, driven by high adoption of technologically advanced devices and an extensive hospital network. More than 70% of the region’s device usage occurs in hospitals and clinics, while ambulatory surgical centers account for around 15%, and dialysis centers cover the remaining share.

North America is sized at USD 15,845.24 million in 2025, capturing 36.0% global share with 6.9% CAGR, underpinned by high device density per bed, broad robotic programs above 35%, and robust ambulatory networks across metropolitan corridors.

North America - Major Dominant Countries in the “Urology Devices Market”

• United States: USD 13,135.70 million, 82.9% regional share, 6.9% CAGR, reflecting comprehensive access to endoscopy, lasers, dialysis infrastructure, and advanced imaging in nationwide health systems.
• Canada: USD 2,012.35 million, 12.7% share, 6.2% CAGR, supported by provincial investment cycles and strong tertiary center coverage.
• Mexico: USD 364.44 million, 2.3% share, 7.1% CAGR, driven by private hospital upgrades in major states.
• Puerto Rico: USD 190.14 million, 1.2% share, 5.8% CAGR, reflecting targeted capital refreshes in select facilities.
• Dominican Republic: USD 142.61 million, 0.9% share, 6.0% CAGR, with focused procurement in urban hospitals.

Europe

Europe holds 27% of the total Urology Devices Market share, supported by strong adoption of minimally invasive technologies and well-established national health systems. Germany, France, and the UK account for more than 55% of Europe’s total demand. Hospitals dominate device usage with 69% share, followed by dialysis centers at 18%, and ambulatory surgical centers at 13%.

Europe totals USD 11,663.86 million in 2025, equal to 26.5% share and 6.5% CAGR, characterized by guideline-based care, high minimally invasive penetration above 47%, and strong university hospital ecosystems across major economies.

Europe - Major Dominant Countries in the “Urology Devices Market”

• Germany: USD 2,857.64 million, 24.5% regional share, 6.1% CAGR, with extensive endoscopy and lithotripsy capacity.
• France: USD 2,204.47 million, 18.9% share, 6.0% CAGR, supported by national hospital networks.
• United Kingdom: USD 1,982.86 million, 17.0% share, 6.2% CAGR, reflecting ASC growth and robotic programs.
• Italy: USD 1,819.56 million, 15.6% share, 6.0% CAGR, driven by device refurbishment and imaging upgrades.
• Spain: USD 1,609.61 million, 13.8% share, 5.9% CAGR, with expanding stone management volumes.

Asia-Pacific

Asia-Pacific accounts for 19% of the Urology Devices Market share and is the fastest-growing regional segment. China, Japan, and India together represent more than 68% of the region’s total demand. Hospitals account for 66% of usage, ambulatory surgical centers for 20%, and dialysis centers for 14%. Ambulatory surgical centers in Asia-Pacific have recorded an 8.78% growth in share, driven by the increasing need for cost-effective, high-throughput facilities.

Asia reaches USD 12,324.07 million in 2025, representing 28.0% global share and 8.8% CAGR, propelled by procedure growth above 10% in key metros, fast ASC penetration at 8.78% share gain, and strong device localization programs.

Asia - Major Dominant Countries in the “Urology Devices Market”

• China: USD 4,683.15 million, 38.0% regional share, 9.4% CAGR, driven by large hospital expansions and fiber-laser adoption.
• Japan: USD 2,588.06 million, 21.0% share, 5.1% CAGR, with entrenched endoscopy and dialysis infrastructure.
• India: USD 2,403.19 million, 19.5% share, 9.6% CAGR, spurred by private chains and day-care models.
• South Korea: USD 1,355.65 million, 11.0% share, 7.2% CAGR, reflecting advanced imaging and robotics installations.
• Indonesia: USD 801.06 million, 6.5% share, 8.1% CAGR, supported by tiered hospital development.

Middle East & Africa

Middle East & Africa currently represents a smaller share of the Urology Devices Market, but growth potential is strong. The region accounts for just under 10% of global demand, with the majority concentrated in Gulf countries and South Africa. Hospitals and clinics dominate usage patterns with 72% share, dialysis centers account for 17%, and ambulatory surgical centers cover 11%.

Middle East and Africa are valued at USD 4,181.38 million in 2025, holding 9.5% share with 7.5% CAGR, characterized by concentrated tertiary hubs, selective robotic installations, and rising dialysis access across urban corridors.

Middle East and Africa - Major Dominant Countries in the “Urology Devices Market”

• Saudi Arabia: USD 1,003.53 million, 24.0% regional share, 7.6% CAGR, featuring high-spec tertiary centers.
• United Arab Emirates: USD 752.65 million, 18.0% share, 7.9% CAGR, with rapid technology adoption in referral hospitals.
• South Africa: USD 919.90 million, 22.0% share, 7.1% CAGR, anchored by mature private networks.
• Egypt: USD 669.02 million, 16.0% share, 7.2% CAGR, reflecting capacity expansion in public hospitals.
• Nigeria: USD 418.14 million, 10.0% share, 7.7% CAGR, driven by metropolitan procurement programs.

List of Top Urology Devices Companies

• Healthtronics
• Teleflex
• Urotech GmbH
• Lumenis
• Intuitive Surgical Inc
• Endo Pharmaceuticals
• KARL STORZ SE & Co KG
• Braun Medical
• Siemens Healthineers
• Coloplast
• Olympus Corporation
• C R Bard
• NIKKISO CO. LTD
• Stryker Corporation
• Fresenius Medical
• Medtronics
• Cook Medical
• Dornier MedTech GmbH
• Boston Scientific Corporation
• UROLOGIX

Top two companies with highest market share

• Boston Scientific Corporation
• Coloplast

Investment Analysis and Opportunities

The 67.58% dominance of instruments makes surgical tools and robotics a prime investment area. Kidney-stone management, holding 36.41% share, ensures continuous demand for lithotripsy and endoscopy devices. Ambulatory surgical centers, with an 8.78% growth rate in share, offer lucrative opportunities for portable and single-use solutions. Asia-Pacific’s expanding healthcare infrastructure and rising hospital capacity support investment in cost-effective, high-volume devices. Companies focusing on minimally invasive tools, which already hold 46.13% share, are positioned to capture the fastest-growing segment.

New Product Development

Innovation is focused on single-use endoscopes, portable laser systems, and robotic platforms. Disposable devices reduce cross-contamination risks by over 30% and lower sterilization time by 35%. Robotic surgery systems are expanding beyond large hospitals to mid-size facilities, increasing adoption rates. AI-integrated imaging is improving early detection accuracy for prostate and bladder conditions. Minimally invasive technologies, already accounting for 46.13% of usage, are being upgraded with better ergonomics, higher precision, and shorter operation times.

Five Recent Developments

• Introduction of high-resolution single-use ureteroscopes, reducing sterilization turnaround by 35%.
• Deployment of compact laser lithotripsy units in 25% more outpatient facilities.
• Expansion of robotic-assisted urology surgery programs to over 30% of tertiary hospitals.
• AI-driven urodynamic testing systems launched in major hospital networks.
• Infection-resistant catheter designs adopted in 20% more long-term care patients.

Report Coverage of Urology Devices Market

The report covers market segmentation by type, application, and region, with detailed analysis of product adoption rates and usage volumes. It highlights instruments at 67.58% share, minimally invasive technologies at 46.13%, and kidney-stone management as the leading disease segment at 36.41%. End-user analysis shows hospitals and clinics holding 68.55% of the market, with ambulatory centers growing their share by 8.78%. Regional coverage includes North America, Europe, Asia-Pacific, and Middle East & Africa, with country-level insights on device penetration. Competitive profiling identifies Boston Scientific and Coloplast as the top two players by market share, alongside a comprehensive list of key competitors.

Urology Devices Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 47218.81 Million in 2026
Market Size Value By	USD 88855.95 Million by 2035
Growth Rate	CAGR of 7.28% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Endoscopes Lasers and Lithotripsy Devices Dialysis Devices Other By Application : Hospitals and Clinics Dialysis Centers Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample